Novavax (NVAX) said Friday it achieved the first milestone under its agreement with Sanofi (SNY), earning a $50 million payment tied to progress in its phase 2/3 trial for a COVID-19 vaccine in children.
The payment marks the first milestone since the partnership began in May, Novavax said. The company could earn up to $300 million in additional milestones related to its COVID-19 vaccine and a further $350 million for combination products under the agreement, alongside tiered royalties on future sales.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments